Alector, Inc.

ALEC · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
123
SEC Filings

Business Summary

PART I Item 1. Bu siness. Overview We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, repla...

Next Earnings

Q2 FY2026 — expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionALECdiscussed_in_filing Cybersecurity
topic_mentionALECdiscussed_in_filing Cybersecurity
topic_mentionALECdiscussed_in_filing Blockchain & Crypto
topic_mentionALECdiscussed_in_filing Healthcare & Bio
topic_mentionALECdiscussed_in_filing Blockchain & Crypto
topic_mentionALECdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-252025-12-310001193125-26-071593EDGAR87K words
2025-02-262024-12-310000950170-25-027758EDGAR—
2024-02-272023-12-310000950170-24-021183EDGAR—
2023-02-282022-12-310000950170-23-005111EDGAR—
2022-02-242021-12-310000950170-22-001979EDGAR—
2021-02-252020-12-310001564590-21-008860EDGAR—
2020-03-242019-12-310001564590-20-012520EDGAR—
2019-03-262018-12-310001564590-19-009358EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269592EDGAR61K words
2025-08-072025-06-300000950170-25-105050EDGAR—
2025-05-082025-03-310000950170-25-066987EDGAR—
2024-11-062024-09-300000950170-24-122328EDGAR—
2024-08-072024-06-300000950170-24-092814EDGAR—
2024-05-082024-03-310000950170-24-055682EDGAR—
2023-11-072023-09-300000950170-23-060270EDGAR—
2023-08-032023-06-300000950170-23-038023EDGAR—
2023-05-042023-03-310000950170-23-017874EDGAR—
2022-11-082022-09-300000950170-22-023249EDGAR—
2022-08-042022-06-300000950170-22-014810EDGAR—
2022-05-052022-03-310000950170-22-007846EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-250001193125-26-071557EDGAR2K words
2025-12-120001193125-25-317554EDGAR—
2025-11-060001193125-25-269537EDGAR—
2025-10-210001193125-25-245102EDGAR—
2025-08-070000950170-25-105023EDGAR—
2025-06-130001193125-25-140731EDGAR—
2025-05-080000950170-25-066945EDGAR—
2025-03-280000950170-25-046756EDGAR—
2025-03-100001193125-25-050448EDGAR—
2025-02-260000950170-25-027734EDGAR—

123 total filings indexed. 93 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001653087
TickerALEC
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 81e2ef4a195aef12714b9deb37ef5970be6297269e3fed17bf4a7e7eb9bbe436
parent: 27867a165524dc0f0c30ef6463ceb1b101091adef0ccac01227b5b12e27bb71e
content hash: 41c2e5356280c753732675bb5df1df5e1b6d1ccf15ef0f368aa5869bb8be146a
signed: 2026-04-13T04:43:34.881Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf